Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery wins Outstanding Achievement Award

Sygnature Discovery have been named as the winner of the Outstanding Achievement award at the Medilink East Midlands Business Awards 2019.

The Medilink Business Awards aim is to highlight the best of the best in the life sciences sector with 7 categories, start-up, export achievement, delivering innovation into health and care, innovation, outstanding achievement, deal of the year and one to watch. The awards ceremony took place on 5th December 2019 at the Radisson Blu East Midlands Airport. The evening began with a networking drinks reception, followed by dinner and the awards presentation by stand-up comedian Jimmy McGhie.

Sygnature were finalist for 2 awards, Outstanding Achievement and Deal of the Year, for the acquisition of the leading preclinical CRO RenaSci. The Outstanding Achievement award was received by Sygnature Discovery’s Dr Paul Clewlow, Senior VP, Business Development, and Anders Lindstrom, Director of Marketing. The Award was sponsored by Pure Drug Safety.

Paul commented: “We are very pleased and privileged to have won the Outstanding Achievement Award. Our aim is to deliver drug candidates and to enable pharmaceutical customers to succeed in developing new treatments ultimately to benefit patients with serious diseases. This award is a great recognition of our track record as well the ability, diligence and dedication of Sygnature Discovery and the science we do.”

The winners are shortlisted for the national Medilink UK Healthcare Business Awards which will take place on the 1st April 2020.

If you have any questions, would like to find out more about Sygnature Discovery or drug discovery in general then we’d love to hear from you. You can get in touch by using any of the contact forms or by emailing us at

Latest News

View All

Sygnature Discovery wins Medilink Outstanding Achievement Award

Sygnature Discovery expands DMPK capabilities with acquisition…

Sygnature and RenaSci strengthen drug abuse leadership…

Sygnature Discovery boosts senior management team with…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.